US 11,939,362 B2
Light-inducible protein aggregation system for modeling proteinopathies and neurodegenerative disorders
Abid Oueslati, Québec (CA)
Assigned to UNIVERSITÉ LAVAL, Québec (CA)
Appl. No. 17/252,323
Filed by UNIVERSITÉ LAVAL, Québec (CA)
PCT Filed Jul. 3, 2019, PCT No. PCT/CA2019/050914
§ 371(c)(1), (2) Date Dec. 15, 2020,
PCT Pub. No. WO2020/006630, PCT Pub. Date Jan. 9, 2020.
Claims priority of provisional application 62/693,666, filed on Jul. 3, 2018.
Prior Publication US 2021/0261634 A1, Aug. 26, 2021
Int. Cl. C07K 14/47 (2006.01); A61N 5/06 (2006.01); C07K 19/00 (2006.01); C12N 15/86 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/4711 (2013.01) [A61N 5/062 (2013.01); C07K 14/4702 (2013.01); C12N 15/86 (2013.01); G01N 33/6845 (2013.01); G01N 33/6896 (2013.01); A61K 38/00 (2013.01); C07K 2319/60 (2013.01); C07K 2319/70 (2013.01); C07K 2319/735 (2013.01); C12N 2750/14143 (2013.01); G01N 2800/2835 (2013.01); G01N 2800/7047 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A light-induced protein aggregate comprising:
(a) a fusion protein comprising an alpha-synuclein polypeptide fused to a photoactivatable polypeptide; and
(b) a proteopathic polypeptide other than alpha-synuclein that self-aggregates under pathogenic conditions,
wherein illumination of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible formation of intracellular protein aggregates comprising the fusion protein and the proteopathic polypeptide.